We are a company mainly dedicated to detecting and developing projects that could have an impact on neurodegenerative diseases. Specifically, we are interested in projects that study what we believe is their root cause, neuroinflammation. Our goal is to catalyze the transfer of these ideas from basic research laboratories to the pharmaceutical industry. We believe that our work will generate shortcuts towards early diagnosis strategies and novel therapeutic approaches for neurodegenerative diseases.
We believe in the potential of public-private ventures, where scientific knowledge from prestigious research organizations is complemented with funding, business capacity, and global connections that SkyBio can offer.
We are currently focusing on repurposing drugs capable of inhibiting aggregation, neuroinflammation, and mitochondrial damage. Other vital and synergistic projects include discovering reliable ways to diagnose neurodegenerative diseases at early stages.
2020 and the SARS-CoV-2 pandemic triggered added a new direction in projects that SkyBio has been developing, since 2017, with prestigious institutions under public-private Research and Development agreements. Always aligned with our Mission to detect and develop projects that have a high impact in medical sciences, and with the aim of catalyzing transfer to the pharmaceutical industry, SkyBio dedicated extensive resources to support Research and Development in the framework of the SARS-COV-2 pandemic, with significant achievements in 2 areas: therapy and detection.